MedTrace Logo

A Study of OSI-7904L Versus 5-FU/LV as Treatment in Patients With Biliary Tract Cancer

NCT00088270 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2006-02-22

No results posted yet for this study

Summary

Multi-center, randomized Phase II study to evaluate the efficacy and safety of OSI-7904Lversus 5 FU/LV in biliary tract cancer.

Conditions

  • Locally Advanced or Metastatic Adenoca of the Biliary Tract

Interventions

DRUG

OSI-7904L

DRUG

5-Fluorouracil/Leucovorin

Sponsors & Collaborators

  • OSI Pharmaceuticals

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-08-31
Completion
2005-08-31

Countries

  • United States
  • Belgium
  • Germany
  • Poland
  • Romania
  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00088270 on ClinicalTrials.gov